Followers | 16 |
Posts | 1145 |
Boards Moderated | 0 |
Alias Born | 03/12/2010 |
Thursday, March 30, 2017 1:27:19 PM
TORONTO, March 30, 2017 /CNW/ - ProMIS Neurosciences ("ProMIS" or the "Company"), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, released today management's review of the first quarter of 2017, which included a review of Q1 accomplishments, a status update on ongoing programs, and its outlook for near term value creation.
Key highlights of the quarterly update include:
•Numerous studies underway and on track to further validate that ProMIS is building a 'best in class' portfolio of therapies targeting toxic, prion-like forms of Amyloid beta, a root cause of Alzheimer's;
•Results announced in January for lead product PMN310 showed prevention of short term memory loss in a well-validated mouse model. ProMIS's other four monoclonal antibodies (mAbs) are undergoing evaluation in the same model, with results expected over the coming months;
•PMN310 on track for IND submission (clinical trial initiation) in late 2018;
•Cohort study underway, evaluating presence and prevalence of ProMIS mAb targets in cerebrospinal fluid (CSF) and blood from Alzheimer's patients, with initial readout expected in the coming months;
•Diagnostics development underway and on track; goal is to create diagnostics to detect different toxic oligomer strains of Amyloid beta in both CSF and blood;
•Discovery programs for TDP43 and Tau, two highly valued targets in neurodegenerative disease and dementia, on track with confirmation of targets and patent submissions expected soon.
"2017 is shaping up to be a very important year for ProMIS, and the year is off to a great start. All our programs are progressing well, and external events continue to support our scientific strategy", said Eugene Williams, Executive Chairman.
"Recently announced results of major clinical trials with competitor products in Alzheimer's strongly support ProMIS' differentiation", stated ProMIS President and CEO, Dr. Elliot Goldstein. "We remain very confident that our mAb programs focused on selectively targeting the toxic, prion-like forms of Amyloid beta will lead to 'best in class therapy' and significant value creation".
Recent PMN News
- ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS • GlobeNewswire Inc. • 04/09/2024 11:00:00 AM
- ProMIS Neurosciences to Present in Upcoming Investor Conferences in April • GlobeNewswire Inc. • 04/04/2024 11:00:00 AM
- ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 04/01/2024 08:15:00 PM
- ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio • GlobeNewswire Inc. • 03/11/2024 11:00:00 AM
- ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine • GlobeNewswire Inc. • 01/22/2024 12:00:00 PM
- ProMIS Neurosciences Issues Letter to Shareholders • GlobeNewswire Inc. • 01/08/2024 12:00:00 PM
- ProMIS Neurosciences, Inc. Announces Leadership Transition • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- ProMIS Neurosciences Announces Publication on Novel Target for ALS • GlobeNewswire Inc. • 12/20/2023 12:00:00 PM
- ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease • GlobeNewswire Inc. • 11/20/2023 12:00:00 PM
- ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 11/14/2023 09:30:00 PM
- ProMIS Neurosciences Closes $20.4 Million Private Placement Financing • GlobeNewswire Inc. • 09/08/2023 11:00:00 AM
- ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/06/2023 04:18:53 PM
- ProMIS Neurosciences Announces $20.4 Million Private Placement Financing • GlobeNewswire Inc. • 08/21/2023 08:12:03 PM
- ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 08/14/2023 09:33:19 PM
- ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline • GlobeNewswire Inc. • 07/17/2023 11:00:00 AM
- ProMIS Announces Completion of Continuance • GlobeNewswire Inc. • 07/14/2023 11:45:00 AM
- ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange • GlobeNewswire Inc. • 07/10/2023 11:55:00 AM
- ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved • GlobeNewswire Inc. • 06/30/2023 12:00:00 PM
- Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time • GlobeNewswire Inc. • 06/29/2023 12:00:00 PM
- ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 05/15/2023 09:00:00 PM
- ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease • GlobeNewswire Inc. • 05/08/2023 01:00:00 PM
- Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease • GlobeNewswire Inc. • 04/25/2023 09:00:00 PM
- ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting • GlobeNewswire Inc. • 04/24/2023 11:30:00 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM